Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing

被引:0
作者
Meixian Jin
Xiao Yi
Wei Liao
Qi Chen
Wanren Yang
Yang Li
Shao Li
Yi Gao
Qing Peng
Shuqin Zhou
机构
[1] Southern Medical University,Department of Anesthesiology, Zhujiang Hospital
[2] Southern Medical University,Department of Gynecology, Zhujiang Hospital
[3] Southern Medical University,General Surgery Center, Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center for Artificial Organ and Tissue Engineering, Guangzhou Clinical Research and Transformation Center for Artificial Liver, Instit
来源
Stem Cell Research & Therapy | / 12卷
关键词
Stem cells; Hepatocyte-like cells; Drug screening; Drug-induced liver injury; 3D cell culture;
D O I
暂无
中图分类号
学科分类号
摘要
Drug-induced liver injury (DILI) is one of the leading causes of clinical trial failures and high drug attrition rates. Currently, the commonly used hepatocyte models include primary human hepatocytes (PHHs), animal models, and hepatic cell lines. However, these models have disadvantages that include species-specific differences or inconvenient cell extraction methods. Therefore, a novel, inexpensive, efficient, and accurate model that can be applied to drug screening is urgently needed. Owing to their self-renewable ability, source abundance, and multipotent competence, stem cells are stable sources of drug hepatotoxicity screening models. Because 3D culture can mimic the in vivo microenvironment more accurately than can 2D culture, the former is commonly used for hepatocyte culture and drug screening. In this review, we introduce the different sources of stem cells used to generate hepatocyte-like cells and the models for hepatotoxicity testing that use stem cell-derived hepatocyte-like cells.
引用
收藏
相关论文
共 752 条
  • [1] Larrey D(2002)Epidemiology and individual susceptibility to adverse drug reactions affecting the liver Semin Liver Dis 22 145-155
  • [2] Verma S(2009)Diagnosis, management and prevention of drug-induced liver injury Gut. 58 1555-1564
  • [3] Kaplowitz N(2020)Epidemiology, predisposing factors, and outcomes of drug-induced liver injury Clin Liver Dis 24 1-10
  • [4] Bjornsson ES(2019)Incidence and etiology of drug-induced liver injury in mainland China Gastroenterology. 156 2230-2241
  • [5] Shen T(2017)Current limitations and future opportunities for prediction of DILI from in vitro Arch Toxicol 91 131-142
  • [6] Liu Y(2014)ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury Am J Gastroenterol 109 950-966
  • [7] Shang J(2019)EASL Clinical Practice Guidelines: drug-induced liver injury J Hepatol 70 1222-1261
  • [8] Xie Q(2017)CSH guidelines for the diagnosis and treatment of drug-induced liver injury Hepatol Int 11 221-241
  • [9] Li J(2017)Transcriptional, functional, and mechanistic comparisons of stem cell-derived hepatocytes, HepaRG cells, and three-dimensional human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury Drug Metab Dispos 45 419-429
  • [10] Yan M(2010)General review on in vitro hepatocyte models and their applications Methods Mol Biol 640 1-40